# Johnson & Johnson Stock Analysis: Trading Near 52-Week High as Analysts Upgrade Outlook
Explore Johnson & Johnson's current stock performance as it trades near its yearly high at $188.95 per share. This episode breaks down recent analyst upgrades from Guggenheim and JP Morgan, who raised their price targets to $200, reflecting growing Wall Street optimism. We analyze the significance of EVP Jennifer Taubert's recent 24% stake reduction and what it means for investor sentiment. With impressive Q2 earnings exceeding expectations ($2.77 EPS vs $2.68 forecast) and revenue growth of nearly 6% year-over-year, J&J continues showing strength in both Innovative Medicine and MedTech divisions. Discover why analysts maintain a "moderate buy" consensus despite executive selling, and what J&J's 2.8% dividend yield and $455 billion market cap mean for healthcare investors watching this pharmaceutical giant's trajectory.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
